Teva partners with Sanofi for Duvakitug development.
5 reports, 3 independent
Updated Aug 5
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Teva partners with Sanofi for Duvakitug development.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Advancing experimental vitiligo treatment (TEV-408) into Phase 2b.1 source
- Teva and Sanofi announce a partnership to develop Duvakitug.
Keep exploring
The entities involved
-
Sanofi
company in Milan, Italy
Nothing else this week.
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
- Teva's acquired product is currently undergoing review by the FDA.
- Teva Pharmaceutical Industries discussed company strategy at an event hosted by Morgan Stanley.
- Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
- Chris Fox, President of Teva USA, discussed drug pricing priorities for American patients.
Coverage
Newest first; wire copies grouped- biopharmadive.com
- fool.comTeva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. | The Motley Fool
- ynetnews.com
- Unknown outlet